Serina Therapeutics
56 hedge funds and large institutions have $13.1M invested in Serina Therapeutics in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
10% more funds holding
Funds holding: 51 → 56 (+5)
0.02% more ownership
Funds ownership: 0.48% → 0.5% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
44% less capital invested
Capital invested by funds: $23.3M → $13.1M (-$10.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$304K |
| 2 |
State Street
Boston,
Massachusetts
|
+$209K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$178K |
| 4 |
BlackRock
New York
|
+$86.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$156K |
| 2 |
Jane Street
New York
|
-$99K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30.4K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$27K |
| 5 |
Bank of New York Mellon
New York
|
-$13.1K |
SER Hedge Fund Activity: Q3 2019 in Review
56 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q3 2019, worth a combined $13.1M — down 44% from $23.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SER positions and 2 closed out — a net gain of 5 holders — while 17 added to existing stakes and 10 trimmed.
The largest buyer was Northern Trust, adding an estimated $304K. The largest seller was Defender Capital, cutting an estimated $156K.
- 56 institutional investors held Serina Therapeutics (SER) as of Q3 2019, up from 51 in Q2 2019.
- Funds reported $13.1M of Serina Therapeutics stock for Q3 2019, down 44% quarter-over-quarter.
- 7 funds opened new Serina Therapeutics positions in Q3 2019 and 2 closed out, a net change of +5 holders.
- The largest Serina Therapeutics buyer in Q3 2019 was Northern Trust, an estimated $304K added.
- The largest Serina Therapeutics seller in Q3 2019 was Defender Capital, an estimated $156K sold.
Based on aggregated 13F filings for Q3 2019.